MedTrace Logo

Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor

NCT00979381 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2010-03-18

No results posted yet for this study

Summary

In this study the researchers investigate the influence of the tyrosine kinase inhibitors sunitinib and sorafenib, on the normal humoral and cellular immuno response to influenza vaccination in patients with metastases of renal cell carcinoma or a GIST.

Conditions

Interventions

BIOLOGICAL

influenza vaccine

influenza vaccination

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • C.M.L. van Herpen, MD, Phd · UMCN st Radboud

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2008-11-30
Completion
2009-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979381 on ClinicalTrials.gov